Table 1 Patient data at study enrollment and after 5 years of uveitis disease
Study enrollment | Initial uveitis visit | 5-year uveitis FU visit | |
|---|---|---|---|
n = 75 | n = 63a (of 75) | n = 57a (of 75) | |
Female, n (%) | 56 (74.7%) | ||
Age [y], mean (SD) | 3.5 (2.1) | ||
Age [y] at JIA onset, mean (SD) | 3.0 (2.0) | ||
Age [y] at uveitis onset, mean (SD) | 4.2 (2.0) | ||
Disease duration [months], mean (SD) | 6.6 (5.1) | ||
Interval JIA and uveitis onset [months], mean (SD) | 14.4 (13.3) | ||
Oligoarthritis, extended, n (%) | 10 (13.3%) | ||
Oligoarthritis, persistent, n (%) | 42 (56.0%) | ||
Psoriatic arthritis, n (%) | 1 (1.3%) | ||
Enthesitis-related arthritis, n (%) | 1 (1.3%) | ||
RF-negative polyarthritis, n (%) | 18 (24.0%) | ||
Other arthritis, n (%) | 3 (4.0%) | ||
ANA positive, n (%) | 64 (85.3%) | ||
HLA-B27 positive, n (%) | 5 (6.7%) | ||
ESR [mm/h], mean (SD) | 29.2 (24.5) | 20.4 (15.8) | 11.1 (8.1) |
CRP [mg/dl], mean (SD) | 11.2 (16.8) | 5.2 (7.9) | 1.2 (2.1) |
S100 A12 [ng/ml], mean (SD) | 362.5 (547.5) | 246.9 (348.5) | 362.5 (547.5) |
Physician’s global assessment, mean (SD) | 3.6 (2.5) | 2.5 (2.2) | 0.9 (1.3) |
Number of joints with active arthritis, mean (SD) | 2.3 (2.5) | 1.3 (1.8) | 0.2 (0.8) |
cJADAS-10, mean (SD) | 8.8 (5.2) | 6.7 (4.2) | 2.4 (2.8) |
Patient's global, mean (SD) | 2.8 (2.3) | 3.0 (2.4) | 1.2 (1.6) |
C-HAQ, mean (SD) | 0.5 (0.6) | 0.5 (0.7) | 0.1 (0.3) |
PedsQL, total, mean (SD) | 72.1 (18.6) | 76.9 (19.2) | 88.7 (9.6) |
PedsQL, physical, mean (SD) | 66.2 (25.3) | 74.1 (24.9) | 92.1 (9.3) |
PedsQL, psychosocial, mean (SD) | 75.7 (16.8) | 78.7 (18.1) | 86.8 (12.2) |